Foundayo Cost: What the GLP-1 Pill Actually Runs

Foundayo is the oral GLP-1 that people have been waiting for since Rybelsus arrived and turned out not to be a weight-loss drug. It is approved, it is priced, and both facts are published, so this page states them from the FDA's and Lilly's own documents rather than from launch coverage. Prices checked 2026-08-29.

What is approved, and when

The FDA approved Foundayo (orforglipron) on April 1, 2026. The approval letter for NDA 220934 covers the use of the tablets "in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition"².

The approval was unusual on process as well as pharmacology. The FDA's announcement calls it "the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program" and the first new molecular entity approved under it, decided 50 days after filing and 294 days ahead of the application's scheduled review date of January 20, 2027¹. That phrasing matters for a reader trying to judge the drug: a fast review is a fast review, not a different standard of evidence, and the agency describes the same two randomized, double-blind, placebo-controlled trials behind it that any obesity approval would rest on¹.

What the label says

Foundayo is a once-daily tablet, and the FDA describes it as "a glucagon-like peptide-1 (GLP-1) receptor agonist in tablet form that should be taken orally once daily"¹. The prescribing information lists six tablet strengths — 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg — and sets the maximum dosage at 17.2 mg once daily, reached by stepping up through the ladder³.

It carries the same boxed warning as the injectables, for thyroid C-cell tumors, and it is contraindicated in anyone with a personal or family history of medullary thyroid cancer or with Multiple Endocrine Neoplasia syndrome type 2¹³. The side-effect profile the FDA lists is the familiar one: nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, fatigue and hair loss among them¹. If hair thinning is the part that worries you, the sourced version is in GLP-1 and hair loss.

What it costs

Lilly publishes a dose ladder, not a single price. The savings terms state: "Regular price for a 1-month supply of Foundayo dosages is $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg"⁴. The self-pay headline on the same page is "Starting at $149 per month," and the word starting is doing real work — that is the lowest strength, which is where you begin and not where you stay⁴.

The $25 figure in the advertising is a savings card, and the card is for insured people whose plan will not pay. Its terms require that you "are enrolled in a commercial drug insurance plan" and are "not enrolled in any state, federal, or government funded healthcare program"⁴. If you have Medicare, the route is different: Medicare.gov lists Foundayo tablets among the products covered for a $50 monthly copay under the Medicare GLP-1 Bridge, the federal demonstration that opened July 1, 2026⁷. That program has its own eligibility test, laid out in Medicare GLP-1 coverage.

What the trial measured

The pivotal obesity trial, ATTAIN-1, randomized 3,127 adults with obesity and without diabetes and ran 72 weeks. Mean weight change from baseline was minus 11.2% on the highest dose studied against minus 2.1% on placebo, and in that highest-dose group 54.6% of patients lost 10% or more of body weight, 36.0% lost 15% or more, and 18.4% lost 20% or more⁵.

Read that against the injectable numbers before deciding. It is a real effect, and it is smaller than what the weekly injections produced in their own trials — a comparison worth making carefully, since the studies were separate. Semaglutide vs tirzepatide sets out those figures with the same caution.

How it compares to Rybelsus

Rybelsus is the other semaglutide tablet, and the reason it never solved the pill question is written into its label: Rybelsus and Ozempic tablets are indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" and to reduce major adverse cardiovascular events in that population⁶. Weight management is not among its approved uses. Foundayo is the first oral GLP-1 approved for weight itself.

On price the two are closer than the indications suggest. Novo Nordisk's own pharmacy prices its semaglutide tablet at "$149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg," with a month defined as one bottle of 30 tablets⁸. Foundayo's ladder starts at the same $149 and tops out $50 higher. The broader oral-versus-injection trade-off is in injections vs oral GLP-1, and the brand-by-brand background is in Rybelsus vs Ozempic.

Who actually lists it

Of the 508 providers tracked here on 2026-08-29, 132 offer an oral GLP-1 route of some kind, but only 18 name orforglipron or Foundayo anywhere in their published copy, and 8 name Rybelsus. The pill is available; it is not yet widely stocked by telehealth clinics, and a listing that says "oral GLP-1" without naming the molecule could mean any of three quite different products.

The manufacturer's own direct channel has its own listing at LillyDirect Foundayo. Among the clinics, the widest published medication list on this site belongs to Found, which carries the pill alongside compounded and brand injectables, and the retail-pharmacy route is covered in the GoodRx listing. If you are weighing the pill against everything else on price, start at best GLP-1 for weight loss or the wider cash-price breakdown in GLP-1 cost without insurance. Sources are indexed in our research library.